Abstract
INTRODUCTION
The use of short-term mechanical circulatory support (MCS) has rapidly expanded for acute haemodynamic decompensation and refractory cardiogenic shock (RCS) [1, 2] . Various types of percutaneous short-term MCS have been developed, and clinical outcomes continue to improve with new technology [1, 2] . Moreover, short-term MCS can serve as a bridge to a long-term destination such as a heart transplant or a durable ventricular assist device (VAD) [3] . However, limitations remain with the short-term MCS devices, including power, durability, special skills needed for insertion and the patient's mobility [3] . Although a VAD has the advantage of providing sufficient support and durability, the standard surgical technique for its insertion requires a median sternotomy and the use of cardiopulmonary bypass. To overcome these drawbacks, we previously developed a minimally invasive apicoaxillary external VAD insertion technique [4] . However, this technique was reserved for patients who could be stabilized with isolated left VAD (LVAD) support. We recently refined this approach by adding an external corporeal membrane oxygenation (ECMO) system in order to include patients with coexisting right ventricular failure and respiratory insufficiency, both of which commonly accompany RCS. We report our experience with a novel minimally invasive surgical approach using an external VAD and ECMO in a series of patients with RCS.
METHODS
Our institutional review board approved this study (registration #AAAE1866). We retrospectively reviewed our experience with the surgical implantation of an external VAD using CentriMag (Thoratec Corporation, Pleasanton, CA) at the Columbia Presbyterian Medical Center between April 2010 and May 2016. During this period, 193 consecutive patients with RCS underwent surgical placement of an external VAD as a bridge to decision therapy. Of these, 25 patients (13%) who underwent minimally invasive external VAD implantation were included in this study.
Indications and surgical technique
All patients underwent external temporary VAD insertion as a bridge to decision therapy. Our algorithm for bridge to decision therapy for RCS has been described previously [3] . RCS is characterized by a systolic blood pressure of <90 mmHg, a cardiac index <2.0 l/min/m 2 , pulmonary capillary wedge pressure >16 mmHg (or evidence of pulmonary oedema in the absence of a pulmonary artery catheter) and evidence of end-organ failure. These patients are rapidly evaluated by our multidisciplinary 'shock team', which includes cardiac surgeons, interventional and heart failure cardiologists, nurse practitioners and intensive care physicians to determine the most suitable short-term MCS device for each patient. From April 2010 to October 2015, our standard surgical approach using CentriMag was external biventricular VAD implantation through a standard sternotomy with cardiopulmonary bypass [3] . During this period, 168 patients underwent the standard sternotomy procedure and 13 patients underwent a minimally invasive procedure because the risk for sternotomy or cardiopulmonary bypass (i.e. redo, coagulopathy) was too high for them. Since November 2015, we used this minimally invasive technique with 12 patients as a standard first choice approach instead of the sternotomy approach. A total of 25 patients underwent minimally invasive external VAD implantation during this study period. Exclusion criteria were mechanical obstacles to cannulation of axillary artery or left ventricular apex (i.e. subclavian artery stenosis, left ventricular thrombus).
Insertion was performed under general anaesthesia with a single-lumen endotracheal tube and without cardiopulmonary bypass. Bilateral radial artery pressures were monitored. The right or left axillary artery was exposed through a small infraclavicular incision, and the left ventricular apex was exposed through a mini-left anterior thoracotomy via the fifth or sixth intercostal space (Fig. 1A) . The patients were given systemic heparin. An 8-mm Dacron graft was sewn onto the axillary artery, and the arterial cannula (EOPA, Medtronic, Inc., Minneapolis, MN) was inserted into the graft. Double mattress sutures buttressed with felt pledgets were placed at the apex, and an inflow cannula (straight venous cannula for cardiopulmonary bypass) was inserted into the left ventricle through a stab wound. The cannula position was confirmed on a transoesophageal echocardiogram. In patients with some degree of right ventricular failure and/or respiratory failure, femoral or jugular venous cannulation (BioMedicus, Medtronic, Inc.) was added as an additional inflow source. In such cases, apical and venous cannulas were connected with a Y-connector, and an oxygenator (Quadrox D, Maquet, Wayne, NJ) was spliced into the circuit as an ECMO system (Fig. 1B) . All cannulas were connected to a CentriMag circuit and support was implemented. The amount of drainage from the apical cannula was adjusted to allow the aortic valve to open periodically, as viewed using transoesophageal echocardiography, to avoid blood stagnation in the aortic root. The blood flow through each inflow and outflow limb was monitored with a transonic flow sensor. The flow ratio of two inflow limbs (apical and venous) can be adjusted with a tube constrictor. If the difference of the mean radial arterial pressure of the perfused side was 20 mmHg more than that of the other side, the axillary artery that bands distal to the cannulation site was added to prevent hyperperfusion.
Postimplant device management
Anticoagulation with intravenous heparin was initiated at the rate of 300 units/h once the chest tube drainage became serosanguinous. A partial thrombin time was measured every 8 h. The dose of heparin was gradually titrated upward and maintained throughout the support with the goal of a partial thrombin time of 60-80 s. Patients were managed by the multidisciplinary shock team, which performed rounds daily. Once end-organ function began to recover and the requirement for vasoactive agents became minimal, removal of the venous limb was considered in patients with ECMO. The flow of the venous limb was gradually weaned to 1.5 l/min under central venous pressure monitoring. Maintenance of central venous pressure <13 mmHg, stable mean arterial pressure (>60 mmHg) and stable drainage flow through the apical limb ensured appropriate right ventricular function. If these parameters were stable, the venous limb was temporarily clamped at the bedside as a final test. Once the venous cannula was removed, we quickly changed the FIO 2 setting on the ECMO oxygenator to 40%. The oxygenator was removed if the oxygenation level was satisfactory (PaO 2 > 100 mmHg) on the minimal ventilator setting. Thereafter, patients underwent evaluation for eligibility for a heart transplant, durable LVAD, or myocardial recovery. Our current strategy is to optimize the clinical conditions as much as possible. Our goal is to have all of the patients achieve extubation and ambulation with an apicoaxillary external VAD and to wait for the normalization of end-organ function before going to the next step.
Data collection and follow-up
All clinical data were collected from chart reviews in the patients' electronic medical records. For each patient, preoperative variables were collected retrospectively. Intraoperative variables included the size of the cannulas used, the cardiopulmonary bypass time and the arterial cannula flow obtained. Early postoperative data included complications occurring while the patients were being supported on the devices. Haemodynamic indices from the Swan-Ganz catheter were obtained before and 12 h after surgery in all patients. In patients who made it to the next step, laboratory data were collected immediately before they underwent the next operation. The follow-up examinations were completed on 30 May 2016 and follow-up was completed in 100% of patients.
Statistical analysis
Stata (Stata Corp, College Station, TX) software was used for statistical analysis. The data are presented as frequencies and percentages for categorical variables and as mean ± standard deviation for continuous variables. Continuous variables were compared with a paired or unpaired t-test. Kaplan-Meier curves were used to represent survival.
RESULTS
The baseline characteristics are listed in Table 1 . The average age was 58 ± 9.1 years. All patients were in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile I. The aetiology of RCS was acute decompensated heart failure in 13 (52%) and acute myocardial infarction in 12 (48%). Eight patients (32%) had a previous history of major cardiac surgery. At the time of implantation, 23 patients (92%) had shortterm MCS devices including an intra-aortic balloon pump in five, peripheral venoarterial ECMO in five, a percutaneous microaxial pump in two, and both a venoarterial ECMO and microaxial pump in 11. The mean duration of short-term MCS prior to surgery was 3.2 ± 2.8 days. Despite short-term MCS support, these patients suffered from sustained end-organ dysfunction. Nineteen patients (76%) were mechanically ventilated. The preoperative calculated HeartMate II risk score was 2.5 ±1.0 [5] .
Intraoperative and postoperative outcomes are listed in Table 2 . All procedures were performed without cardiopulmonary bypass. The average flow obtained was 5.3 ± 1.1 l/min. The ECMO system described above was used in 17 patients (68%). A higher flow rate was obtained in patients with two inflows compared with only an apical inflow (5.7 ± 0.82 vs 4.4 ± 1.1 l/min, P = 0.0023). All patients were successfully weaned off the venous cannula after 4.6 ± 3.6 days of support. One patient required reinsertion of the venous limb due to progressive right ventricular dysfunction associated with ventricular arrhythmia. The mean duration of the external VAD support was 28 ± 14 days. During the support period, four patients died while on the device; two died of multiorgan failure; and two died of a major stroke. Four were withdrawn from the device because they were considered ineligible for a durable VAD and a transplant. Overall, the inhospital mortality rate was 32%. Major complications during the support period included major bleeding requiring transfusion in seven (28%), embolic stroke in four (16%) and respiratory failure requiring tracheostomy in four (16%). Two of the strokes occurred when anticoagulation therapy was stopped because of significant gastrointestinal tract bleeding, and one patient had a hypercoagulation disorder. One patient required conversion of the outflow to the ascending aorta due to excessive bleeding from the axillary cannulation site. No patients developed hyperperfusion of the upper extremity requiring revision of the arterial outflow. Seventeen patients (68%) survived to the next destination. Of those, 14 patients (82%) were extubated and participated in ambulatory rehabilitation with an external VAD before transition to a long-term destination. The external VAD was explanted in three (12%) because of adequate myocardial recovery after 19, 29 and 48 days of support; 12 (48%) underwent device exchange to a durable LVAD after 24 ± 13 days of support; and two (8%) underwent heart transplants after 25 and 48 days of support, respectively. The Kaplan-Meier survival rate at 6 months and 1 year was 92% and 77%, respectively. Table 3 demonstrates the haemodynamic variables before and 12 h after support. The support provided by the device resulted in a significant decrease in pulmonary artery pressure (PAP) compared with baseline: systolic PAP decreased from 44 ± 14 to 37 ± 15 mmHg (P = 0.0016); diastolic PAP decreased from 23 ± 5.8 to 18 ± 5.0 mmHg (P = 0.0011); and the mean PAP decreased from 29 ± 8.8 to 24 ± 8.6 mmHg (P = 0.0037). In patients who reached the next destination (n = 17), end-organ function improved during the period of support: the blood urea nitrogen level went from 41 ± 27 to 19 ± 9.8 mg/dl (P = 0.029) and the creatinine level, from 1.8 ± 1.0 to 1.2 ± 0.57 mg/dl (P = 0.028) ( Table 4) .
DISCUSSION
This series includes patients with RCS whom we have treated using our unique surgical approach with an external continuousflow VAD and ECMO system. Although the number of patients is small, this study demonstrated several potential benefits of this approach as a bridge to the next destination: (i) it provides longer support times with sufficient flow than current percutaneous short-term MCS devices, (ii) biventricular unloading is possible without sternotomy and the use of cardiopulmonary bypass, and (iii) it can be used as a cardiopulmonary rescue method because it combines VAD and ECMO.
Mortality rates for patients with RCS remain high. Recent advances in technology enable us to treat patients with RCS with various percutaneous short-term MCS devices. However, each device still has limitations in terms of flow capability, requirement of special skill for insertion, ventricular unloading effect and durability [2] . In our programme, we prefer ECMO and the surgical implantation of the CentriMag biventricular VAD because they provide both greater circulatory support and full biventricular support [3, 6] . However, traditional venoarterial ECMO is limited by adverse haemodynamics due to increases in afterload with left ventricular loading rather than unloading. In addition, patients cannot ambulate with it. CentriMag biventricular VAD implantation through the conventional sternotomy approach with cardiopulmonary bypass is limited because of its invasiveness and the risk of bleeding in patients with RCS. Our technique permits flexibility in the application of these two modalities to treat patients with RCS.
Because of the convenience and the fact that the procedure is less invasive, percutaneous short-term MCS methods such as ECMO and the microaxial pump have become the treatment of choice for RCS patients at our centre. Most of patients in this study were already supported by percutaneous short-term MCS for a mean of 3 days. Despite this support, our patient cohort suffered from multiple end-organ dysfunctions including liver, kidney and respiratory failure as well as pulmonary venous hypertension representing insufficient flow and left ventricular unloading prior to surgery. Direct unloading of the left ventricle and providing adequate flow by surgical VAD allowed 17 of 25 patients (68%) to recover from multiorgan failure status and eventually reach the next destination. Another limitation of percutaneous short-term MCS is the restriction of patients' mobility because the majority of the available devices requires access to a femoral vessel. Fourteen patients could be extubated and could ambulate with this external VAD.
Placement of a durable VAD could be an option, although not all patients with RCS necessarily need a durable VAD. Favourable outcomes with the minimally invasive off-pump VAD implantation technique using the HeartWare (HeartWare International, Inc., Framingham, MA) VAD were reported in a less sick population [7, 8] . This technique may allow us to reduce the risk of perioperative bleeding and further end-organ damage. However, the outcome with durable VAD placement is known to be poor in patients with INTERMCAS profile I [9] . A recent study showed that patients with a high HeartMate II risk score (>2.48) within the INTERMACS profile I cohort were found to have a significantly high 90-day mortality rate of 39% [10] . The mean HeartMate II risk score in our cohort was 2.5. Another approach could be the placement of a primary durable LVAD concomitant with a right VAD with or without an oxygenator [11] . However, again, outcomes with the insertion of a biventricular assist device are known to be poor even with elective procedures for less sick populations [9, 12] . Our patients comprised an extremely highrisk cohort who underwent an extensive operation to insert a durable VAD at the time of ongoing shock. When one first encounters a patient with RCS, is often unclear whether the person is a candidate for a durable VAD or a transplant. In addition, because of the acuity of the illness, the time available to make a decision is limited. In the present series, four patients turned out to be ineligible for a durable VAD or a transplant and supporting device was withdrawn despite the fact that the patients recovered from RCS. We believe that the most rational approach to developing the best bridging strategy for a high-risk patient with RCS is to (i) determine whether the person is an appropriate candidate for a durable VAD, (ii) optimize the patient's condition to improve the outcome, and (iii) identify an appropriate goal for each patient (i.e. recovery, transplant, durable VAD). Most of our patients required heart replacement therapy as the long-term destination because of extensive myocardial damage. In these cases, this sternum-sparing approach was beneficial to the patient at the time of the last destination surgery. We had seven patients who had not had a prior sternotomy in whom an external VAD was exchanged for a durable VAD. These patients had minimal adhesions inside the pericardium. Therefore, we currently use our minimally invasive technique as the treatment of choice rather than the conventional sternotomy approach.
An additional advantage of this technique is the ability to integrate an ECMO system with a VAD in patients with severe respiratory lung injury or coexisting right ventricular dysfunction. We often encounter patients with RCS who have acute lung injury/ pulmonary oedema and some degree of biventricular dysfunction. Also, an LVAD can induce right ventricular failure by septal shifting [13] . In this situation, adding an ECMO system with a temporary venous limb and an oxygenator can provide partial volume unloading of the right ventricle and sufficient oxygenation through the upper extremity. Once the patient's condition is stabilized, we can easily convert this ECMO-VAD system to an external VAD by eliminating the venous limb. The patient can ambulate with an apicoaxillary external VAD. In our study, 17 patients (68%) required ECMO in addition to an external VAD. All could be weaned off ECMO support because our patients had predominantly left ventricular dysfunction and related pulmonary oedema. In cases with predominantly right ventricular dysfunction or severe lung injury, prolonged ECMO support might be required.
The most frequent complication was major bleeding events requiring transfusion(s). Bleeding was often attributed to the preoperative use of antiplatelet agents, especially in patients with acute myocardial infarction or preoperative shock liver. However, in our early experience, the cannulation sites, especially those for the axillary artery, were occasionally identified as the source. We therefore have modified our technique to reinforce the anastomosis site. We reinforce the axillary anastomosis with bovine pericardial strips and apply Bioglue (CryoLife, Inc., Kennesaw, GA). Another important complication was cerebrovascular accident. Patients with a CentriMag VAD had a higher incidence of stroke than those with an implantable LVAD [3] . We aggressively start anticoagulation therapy within 12 h after surgery and let the aortic valve open periodically by adjusting the apical drainage flow and using inotropes to avoid aortic root thrombus formation.
This study has several limitations. First, it was a retrospective analysis of a single-centre experience. Second, the number of patients was small, which limits its statistical power. Third, because of the nature of single-centre studies, the outcomes described here are based on patients from our practice in terms of selection, surgery and management. Therefore, our findings may not be applicable to other centres.
In summary, this study shows the feasibility of using a minimally invasive external VAD-ECMO system implantation technique as a bridge to decision therapy, especially for patients with profound cardiogenic shock refractory to percutaneous short-term MCS support. Although further experience with this technique is required, satisfactory outcomes can be achieved for the cohort of patients who would otherwise have had a poor prognosis.
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